IRIS PubliCatt

Pane, Marika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.413
NA - Nord America 4.061
AS - Asia 1.117
AF - Africa 35
SA - Sud America 31
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.666
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.026
DE - Germania 1.279
IT - Italia 990
SE - Svezia 744
CN - Cina 483
IE - Irlanda 360
SG - Singapore 339
FR - Francia 202
UA - Ucraina 194
RU - Federazione Russa 163
GB - Regno Unito 158
IN - India 97
FI - Finlandia 95
TR - Turchia 48
HK - Hong Kong 37
IR - Iran 35
BE - Belgio 31
CZ - Repubblica Ceca 28
NL - Olanda 28
ES - Italia 27
JP - Giappone 23
CI - Costa d'Avorio 22
CH - Svizzera 21
CA - Canada 17
BR - Brasile 15
PL - Polonia 15
KR - Corea 14
RO - Romania 13
MK - Macedonia 12
PA - Panama 12
RS - Serbia 11
IL - Israele 10
AR - Argentina 9
EG - Egitto 9
AT - Austria 8
MX - Messico 5
PT - Portogallo 5
AU - Australia 4
DK - Danimarca 4
HR - Croazia 4
HU - Ungheria 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
TW - Taiwan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
CL - Cile 3
CO - Colombia 3
TH - Thailandia 3
BD - Bangladesh 2
BG - Bulgaria 2
BT - Bhutan 2
EE - Estonia 2
GR - Grecia 2
LK - Sri Lanka 2
LV - Lettonia 2
MA - Marocco 2
PK - Pakistan 2
SA - Arabia Saudita 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
GL - Groenlandia 1
ID - Indonesia 1
KZ - Kazakistan 1
LT - Lituania 1
ME - Montenegro 1
MT - Malta 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PY - Paraguay 1
QA - Qatar 1
VN - Vietnam 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.666
Salva come PNG Salva come JPEG
Città #
Chandler 993
Ashburn 446
Dublin 326
New York 251
Singapore 211
Rome 181
Milan 167
San Mateo 150
Jacksonville 117
Moscow 117
Marseille 104
Nanjing 98
Wilmington 93
Nürnberg 91
Boston 88
Princeton 78
Dearborn 77
Ann Arbor 70
Woodbridge 66
Houston 58
Munich 56
Beijing 48
Bremen 48
Seattle 45
Los Angeles 44
Fairfield 43
Helsinki 42
Nanchang 41
Chicago 33
Redwood City 33
Lawrence 31
Palermo 30
Boardman 28
Hebei 27
Hong Kong 27
Lancaster 26
Brussels 25
Pune 25
Brno 24
Cattolica 24
Detroit 24
Augusta 23
Abidjan 22
Shanghai 22
Izmir 21
Kish 21
Norwalk 21
Jiaxing 20
Jinan 18
Leawood 18
Redmond 17
Shenyang 17
Turin 17
University Park 17
Changsha 16
Washington 16
London 15
Busto Arsizio 14
Tianjin 14
Andover 13
Florence 13
Inverigo 13
Fremont 12
Bologna 11
Cambridge 11
Ningbo 11
Seoul 11
Kunming 10
Lappeenranta 10
Menlo Park 10
Mountain View 10
Salamanca 10
Skopje 10
Toronto 10
Zhengzhou 10
Bari 9
Guangzhou 9
Hangzhou 9
São Paulo 9
Madrid 8
Monza 8
Naaldwijk 8
Naples 8
Nuremberg 8
Tokyo 8
Zurich 8
Edinburgh 7
Genoa 7
San Francisco 7
Taizhou 7
Vienna 7
Amsterdam 6
Cairo 6
Cinisello Balsamo 6
Krakow 6
Niš 6
San Diego 6
Stockholm 6
Istanbul 5
Paris 5
Totale 5.189
Salva come PNG Salva come JPEG
Nome #
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 255
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 209
Cortical visual function in preterm infants in the first year. 205
Neurological examination of preterm infants a term equivalent age 184
Neurological examination at 6 to 9 months in infants with cystic periventricular leukomalacia 161
Crossed cerebellar atrophy of prenatal onset 156
Prognostic value of EEG performed at term age in preterm infants. 151
-Thalamic atrophy in infants with PVL and cerebral visual impairment 137
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care? 124
Visual development in prenatal post-haemorragic ventricular dilatation 122
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. 121
Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation 119
Performance of Upper Limb module for Duchenne muscular dystrophy 119
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. 116
Muscle MRI in Becker muscular dystrophy 116
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 107
Muscle MRI in Becker muscular dystrophy 101
A current approach to heart failure in Duchenne muscular dystrophy 101
Congenital muscular dystrophies with cognitive impairment. A population study 98
Muscle MRI: Out of the tunnel. 97
Salbutamol increases serviva motor neuron (SMN) patients: relevance for clinical trial design 97
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study 97
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 97
Revised upper limb module for spinal muscular atrophy: Development of a new module 96
Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine 95
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy 92
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study 92
Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype 91
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy 91
24 month longitudinal data in ambulant boys with duchenne muscular dystrophy 88
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 85
MRI: Out of the tunnel. 82
Predominant distal muscle involvement in spinal muscular atrophy 82
-Electroclinical patterns and evolution of epilepsy in the 4p- syndrome 79
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 78
Developmental milestones in type I spinal muscular atrophy 77
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 76
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 75
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 72
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 72
Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era 71
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol 69
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 69
Developmental milestones in type I spinal muscular atrophy 67
A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues". 67
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 67
Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study 67
Histological effects of givinostat in boys with Duchenne muscular dystrophy 66
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 65
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 65
6 minute walk test in duchenne MD patients with different mutations:12 month changes 64
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 63
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 63
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 63
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 63
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 63
SEPN1-related myopathies: clinical course in a large cohort of patients 62
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 62
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 62
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis 60
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 60
Longitudinal assessments in discordant twins with SMA 60
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 58
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 58
Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy? 57
New Mutations in NEB Gene Discovered by Targeted Next-Generation Sequencing in Nemaline Myopathy Italian Patients 57
Longitudinal natural history in young boys with Duchenne muscular dystrophy 57
Assessing floppy infants: a new module 57
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 56
Implicit learning deficit in children with Duchenne muscular dystrophy: Evidence for a cerebellar cognitive impairment? 55
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 55
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 55
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 54
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 53
Pediatric Motor Inflammatory Neuropathy: The Role of Antiphospholipid Antibodies. 53
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 53
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 52
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 51
Muscle magnetic resonance imaging in congenital myopathies due to ryanodine receptor type 1 gene mutations 50
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 50
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 50
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 49
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 49
Nusinersen in type 0 spinal muscular atrophy: should we treat? 49
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 49
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 48
Duchenne muscular dystrophy: Preliminary experience with sacubitril-valsartan in patients with asymptomatic left ventricular dysfunction 48
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 48
Clinical Variability in Spinal Muscular Atrophy Type III. 47
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 47
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 46
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 46
The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study 46
Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase 46
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 46
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 45
Development of an academic disease registry for spinal muscular atrophy 45
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy 44
Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. 44
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 44
Totale 7.848
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.605
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.605
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020587 0 0 38 31 54 73 105 26 47 60 114 39
2020/2021502 44 43 15 38 47 43 73 12 62 30 90 5
2021/20221.137 80 37 21 110 80 38 23 192 68 67 208 213
2022/20233.068 302 382 200 459 193 393 217 271 382 48 142 79
2023/20242.604 109 459 99 176 101 401 351 102 52 129 269 356
2024/2025295 124 99 72 0 0 0 0 0 0 0 0 0
Totale 9.921